Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma Services AG
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A multicenter, randomized, double-blind, double dummy, placebo controlled crossover study, to investigate the 24 hour FEV1 profile of a single dose of QMF Twisthaler® (500/400 μg o.d.) delivered in the evening in adult patients with persistent asthma using fluticasone propionate/salmeterol (250/50 μg b.i.d.) as an active control
To evaluate bronchodilator effects of QMF Twisthaler® 500/400 μg o.d. (2x 250/200 μg) administered in the evening compared with placebo in terms of change from (period) baseline FEV1 to 24 hr post-dos...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
safety and efficacy of ruxolitinib in anemic myelofibrosis patients
To determine the spleen length response rate at Week 24
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes
• To demonstrate the efficacy of vildagliptin MR (12.5 mg bid or 25 mg bid) as add-on therapy to metformin in patients with T2DM by testing the hypothesis that the HbA1c reduction with vildagliptin MR...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Flora to provide confirmation: "A study evaluating the efficacy of QGE031 compared to omalizumab in patients with allergic asthma
To compare the effects of treatment every two weeks with 240 mg QGE031 versus omalizumab in changing the concentration of inhaled allergen that is required to elicit a 15% fall in the forced expirato...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Study of the efficacy and safety of secukinumab in patients with active psoriatic arthritis with axial skeleton involvement
To demonstrate that secukinumab 300 mg s.c. is superior to placebo in the achievement of ASAS 20 response at Week 12.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), receiving enzyme inducing anticonvulsant drugs (EIACDs)
To assess the clinical efficacy of the combined treatment of imatinib plus HU based on the objective overall response (OR) rate. The objective overall response rate is calculated as the rate of best o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, controlled extension study of CACZ885H2356 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective
The primary objective of this study is to confirm the long-term safety and tolerability of canakinumab 150 mg subcutaneously (s.c) compared to triamcinolone acetonide 40 mg intramuscularly (i.m).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR® Depot and RAD001 10 mg/d or Sandostatin LAR® Depot and placebo
To determine whether treatment with RAD001 10 mg/d plus Sandostatin LAR® Depot prolongs the progression free survival (PFS) compared to treatment with Sandostatin LAR® Depot alone in patients with adv...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in patients with essential hypertension
To evaluate the efficacy of any of 4 dose regimens (0.25 mg QD, 0.5 mg QD, 1.0 mg QD and 0.5 mg BID) of LCI699 in patients with essential hypertension by testing the hypothesis that the reduction in m...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly
To compare the proportion of patients achieving biochemical control defined as mean GH levels < 2.5 µg/L and normalization of sex- and age-adjusted IGF-1 at 24 weeks with pasireotide LAR 40 mg and pas...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
23
24
25
26
27
28
29
30
31
32
Suivant